SIGNATUREFD, LLC - IONIS PHARMACEUTICALS INC ownership

IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 289 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.

Quarter-by-quarter ownership
SIGNATUREFD, LLC ownership history of IONIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$16,602
-15.0%
366
-23.1%
0.00%
Q2 2023$19,530
+146.2%
476
+114.4%
0.00%
Q1 2023$7,934
-9.1%
222
-3.9%
0.00%
Q4 2022$8,725
-20.7%
231
-6.9%
0.00%
Q3 2022$11,000
+22.2%
248
+2.5%
0.00%
Q2 2022$9,000
-55.0%
242
-55.3%
0.00%
-100.0%
Q1 2022$20,000
-4.8%
541
-20.0%
0.00%0.0%
Q4 2021$21,000
-30.0%
676
-23.7%
0.00%0.0%
Q3 2021$30,000
-23.1%
886
-8.9%
0.00%
-50.0%
Q2 2021$39,000
+11.4%
973
+24.9%
0.00%0.0%
Q1 2021$35,0000.0%779
+24.6%
0.00%0.0%
Q4 2020$35,000
+12.9%
625
-5.0%
0.00%0.0%
Q3 2020$31,000
-13.9%
658
+7.0%
0.00%0.0%
Q2 2020$36,000
+16.1%
615
-5.8%
0.00%
-33.3%
Q1 2020$31,000
-16.2%
653
+7.2%
0.00%0.0%
Q4 2019$37,000
-7.5%
609
-9.5%
0.00%0.0%
Q3 2019$40,000
-7.0%
6730.0%0.00%
-25.0%
Q2 2019$43,000
-17.3%
673
+5.5%
0.00%0.0%
Q1 2019$52,000
+48.6%
638
-2.6%
0.00%
+33.3%
Q4 2018$35,0000.0%655
-3.5%
0.00%
-25.0%
Q3 2018$35,000
+16.7%
679
-4.2%
0.00%
+33.3%
Q2 2018$30,000
+130.8%
709
+132.5%
0.00%
+50.0%
Q1 2018$13,000
+85.7%
305
+59.7%
0.00%
+100.0%
Q3 2016$7,000
+133.3%
191
+344.2%
0.00%0.0%
Q4 2015$3,000430.00%
Other shareholders
IONIS PHARMACEUTICALS INC shareholders Q3 2016
NameSharesValueWeighting ↓
Bellevue Group AG 9,463,400$418,566,0006.01%
Tweedy, Browne Co LLC 2,722,988$120,438,0005.30%
BVF INC/IL 2,872,953$127,071,0005.25%
Sicart Associates LLC 253,976$11,233,0003.98%
Parkman Healthcare Partners LLC 241,945$10,701,0003.04%
Camber Capital Management LP 1,925,000$85,143,0002.61%
Privium Fund Management B.V. 148,807$6,589,0002.39%
SECTOR GAMMA AS 164,223$7,264,0001.87%
HANSEATIC MANAGEMENT SERVICES INC 10,993$486,0001.31%
BRANDYWINE MANAGERS, LLC 8,460$374,0001.23%
View complete list of IONIS PHARMACEUTICALS INC shareholders